Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | DRD4 | P21917 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tandospirone SCHEMBL4445506 | 1.00 | DRD2 (1.00) | DRD2HTR1ADRD4 | |
| Tandospirone SCHEMBL13532602 | 1.00 | DRD2 (1.00) | DRD2HTR1ADRD4 | |
| Tandospirone SCHEMBL22693814 | 1.00 | DRD2 (1.00) | DRD2HTR1ADRD4 | |
| Tandospirone SCHEMBL22381099 | 1.00 | DRD2 (1.00) | DRD2HTR1ADRD4 | |
| Tandospirone SCHEMBL16339864 | 0.99 | DRD2 (1.00) | DRD2HTR1ADRD4 | |
| Tandospirone SCHEMBL1766255 | 0.99 | DRD2 (1.00) | DRD2HTR1ADRD4 | |
| SCHEMBL10925913 | 0.95 | DRD2 (0.90) | DRD2HTR1ADRD4 | |
| Hydrochloric Acid SCHEMBL11011731 | 0.94 | DRD2 (0.91) | DRD2HTR1ADRD4 | |
| Tandospirone SCHEMBL15383602 | 0.92 | DRD2 (0.85) | DRD2HTR1ADRD4 | |
| Tandospirone SCHEMBL15383590 | 0.92 | DRD2 (0.84) | DRD2HTR1ADRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 4327 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12636259-B2 | Transdermal absorption preparation | Sumitomo Pharma Co., Ltd. (JP) | 2026-05-26 | — | — | US | claimed |
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS INC (US) | 2025-09-25 | — | — | US | claimed |
| WO-2025151884-A1 | USE OF GLYCOSAMINOGLYCAN SULFATED POLYSACCHARIDES SUCH AS SODIUM PENTOSAN POLYSULFATE IN COMBINATION WITH PERMEATION AGENTS TO TREAT ALZHEIMER'S DISEASE | PARSONS C LOWELL (US) | 2025-07-17 | — | — | WO | claimed |
| US-12350379-B2 | Extended release pharmaceutical formulation and methods of treatment | DOUGLAS PHARMACETICALS LTD (NZ) | 2025-07-08 | — | — | US | claimed |
| US-20250213593-A1 | Use of Derivatives based on Sarsasapogenin Structure and Pharmaceutical Compositions thereof | BEIJING PHYTOVENT PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2025-07-03 | — | — | US | claimed |
| EP-4570250-A2 | COMBINATIONS COMPRISING BREXPIPRAZOLE OR A SALT THEREOF AND A SECOND DRUG FOR USE IN THE TREATMENT OF A CNS DISORDER | Otsuka Pharmaceutical Co., Ltd. (JP) | 2025-06-18 | — | — | EP | claimed |
| US-20250177385-A1 | COMBINATIONS COMPRISING BREXPIPRAZOLE OR A SALT THEREOF AND A SECOND DRUG FOR USE IN THE TREATMENT OF A CNS DISORDER | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2025-06-05 | — | — | US | claimed |
| CN-119896653-A | Percutaneous absorption preparation | 湖南慧泽生物医药科技有限公司 | 2025-04-29 | — | — | CN | claimed |
| CN-116283926-B | Preparation method of tandospirone citrate and application of tandospirone citrate in preparation | 重庆圣华曦药业股份有限公司 | 2025-02-25 | — | — | CN | claimed |
| CN-119438406-A | Detection method of related substances in tandospirone citrate | 四川科瑞德制药股份有限公司 | 2025-02-14 | — | — | CN | claimed |
| US-5688518-A | Antidepressive therapy | ALZA CORPORATION (US) | 1997-11-18 | — | — | US | claimed |
| WO-1997041878-A1 | TREATMENT OF MOOD DISORDERS WITH A GROWTH HORMONE SECRETAGOGUE | MERCK & CO., INC. (US) | 1997-11-13 | — | — | WO | claimed |
| EP-0510837-B1 | Synergistic combinations in the treatment of anxiety | PFIZER (US) | 1997-09-03 | — | — | EP | claimed |
| EP-0681473-A1 | COMPOSITIONS CONTAINING TANDOSPIRONE OR ITS ANALOGS | ALZA CORPORATION (US) | 1995-11-15 | — | — | EP | claimed |
| WO-1994016699-A1 | COMPOSITIONS CONTAINING TANDOSPIRONE OR ITS ANALOGS | ALZA CORPORATION (US) | 1994-08-04 | — | — | WO | claimed |
| US-5330762-A | Tandospiaine antidepressive therapy | ALZA CORPORATION (US) | 1994-07-19 | — | — | US | claimed |
| US-5246710-A | Dosage form for treating cyclothymia | ALZA CORPORATION (US) | 1993-09-21 | — | — | US | claimed |
| US-5246711-A | Dosage form for treating dysthymia | ALZA CORPORATION (US) | 1993-09-21 | — | — | US | claimed |
| US-5185158-A | Dosage form comprising succinimide drug for treating depressive disorders and composition comprising same | ALZA CORPORATION (US) | 1993-02-09 | — | — | US | claimed |
| EP-0510837-A2 | Synergistic combinations in the treatment of anxiety | PFIZER INC. (US) | 1992-10-28 | — | — | EP | claimed |